Bulletin from Artimplant AB's Annual Meeting of Stockholders 2010

Regulatory News:

Artimplant AB (STO:ARTIB)

Adoption of financial statements, disposition of result and discharge of directors and officers The financial statements of 2009 for the group and the parent company were adopted. The Annual Meeting decided to set off the parent company’s retained loss of SEK 13,282,277 against the statutory reserve. The directors and officers of the Company were granted discharge.

Election of Board members and auditor Ingemar Kihlström was re-elected as chairman of the Board and Anna Malm Bernsten, Wenche Rolfsen Sandsborg and Mats Lindquist were reelected as ordinary Board members. Håkan Johansson was elected as new ordinary Board member. Ernst & Young AB was re-elected as auditor with Björn Grundvall as new responsible auditor.

Adoption of fees The Annual Meeting decided that the fee to the Board of Directors shall be unchanged and be SEK 280,000 to the chairman and SEK 140,000 to ordinary Board members. It was also decided that the fee to the chairman of the audit committee shall be SEK 40,000 and the fee to the other members shall be SEK 20,000 and that the fee to the chairman of the remuneration committee shall be SEK 20,000 and to the other members of the committee SEK 10,000. The audit fee will the upcoming year be in accordance with new agreement for audit services, SEK 200,000 per year.

Election committee The Annual Meeting decided that the election committee before the Annual Meeting of 2010, planned to May 2011, shall be appointed by representatives from the three largest stockholders, according to voting power, as of September 30, 2010.

Principles for remuneration to senior management The Annual Meeting adopted the principles for remuneration to senior management as suggested by the Board of Directors.

All above decisions were taken unanimously.

Consultant physician Jan Lidström, M.D., PhD, orthopaedic surgeon at the Sahlgrenska University Hospital, presented his positive experiences with Artelon® products in a number of indications.

The presentation made by the CEO at the Annual Meeting is available at the Company’s web page: http://www.artimplant.com/investors-media/presentations.html

About Artimplant
Artimplant’s mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal.

Artimplant is a medical technology company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant produces implants for the treatment of osteoarthritis in hands and feet, shoulder and other soft tissue injuries as well as oral and veterinary applications. The Company's products are sold through licensees and own sales under Artimplant’s brand take place through agents and distributors.

Artimplant is a public company listed on the NASDAQ OMX Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on May 5 2010 at 8:45 AM (CET).

Further information is available at www.artimplant.com. To subscribe to future press releases please go to www.artimplant.com/investors-media/subscribe-to-press-releases.html

This information was brought to you by Cision http://www.cisionwire.com